Neuralink, Elon Musk's Brain Implant is Approved for Clinical Trials

 Had not followed this before, will continue ...

Neuralink says it has the FDA’s OK to start clinical trials

Company isn't enrolling patients yet, but it has cleared a major hurdle.

 - John Timmer  in   Arstechnica

In December 2022, founder Elon Musk gave an update on his other, other company, the brain implant startup Neuralink. As early as 2020, the company had been saying it was close to starting clinical trials of the implants, but the December update suggested those were still six months away. This time, it seems that the company was correct, as it now claims that the Food and Drug Administration (FDA) has given its approval for the start of human testing.

Neuralink is not ready to start recruiting test subjects, and there are no details about what the trials will entail. Searching the ClinicalTrials.gov database for "Neuralink" also turns up nothing. Typically, the initial trials are small and focused entirely on safety rather than effectiveness. Given that Neuralink is developing both brain implants and a surgical robot to do the implanting, there will be a lot that needs testing.

It's likely that these will focus on the implants first, given that other implants have already been tested in humans, whereas an equivalent surgical robot has not.

The news is undoubtedly a relief for both the staff of the company and its owner Musk, given that Neuralink has had several negative interactions with federal regulators of late. It's a bad sign when having an earlier bid to start clinical trials rejected by the FDA was the least of the company's problems. The company has also been accused of being abusive toward its research animals and violating transportation rules by shipping implants contaminated with monkey tissue and pathogens.

Typically, when the FDA rejects an application for clinical trials, it is willing to communicate in detail why it found the plan for trials insufficient. It's a positive sign for Neuralink that the company was able to address the concerns of federal regulators in a relatively short period. ... '